A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis

被引:0
作者
Jin Hong
Jiahui Huang
Lili Shen
Siji Zhu
Weiqi Gao
Jiayi Wu
Ou Huang
Jianrong He
Li Zhu
Weiguo Chen
Yafen Li
Xiaosong Chen
Kunwei Shen
机构
[1] Shanghai Jiao Tong University School of Medicine,Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital
来源
BMC Cancer | / 20卷
关键词
Toremifene; Tamoxifen; Breast cancer; Premenopausal patients; Safety; Quality of life;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 172 条
[1]  
Waks AG(2019)Breast cancer treatment: a review JAMA 321 288-300
[2]  
Winer EP(2017)De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer Ann Oncol 2017 28 1700-1712
[3]  
Curigliano G(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816
[4]  
Burstein HJ(2012)Clinical and biomarker predictors of side effects from tamoxifen Breast Cancer Res Treat 132 1107-1118
[5]  
E PW(2005)Ovarian cysts in tamoxifen-treated women with breast cancer Eur J Obstet Gynecol Reprod Biol 120 104-106
[6]  
Gnant M(2009)Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766-776
[7]  
Dubsky P(2005)Ovarian cyst formation in patients using tamoxifen for breast cancer Jpn J Clin Oncol 35 607-611
[8]  
Loibl S(2004)Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations Breast Cancer Res Treat 88 9-16
[9]  
Davies C(2016)Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients Breast 28 67-72
[10]  
Pan H(2014)Toremifene for breast cancer: a review of 20 years of data Clin Breast Cancer 14 1-9